Arbutus Biopharma Corp (ABUS) vs Seaport Therapeutics, Inc. Common Stock (SPTX)

A side-by-side comparison of Arbutus Biopharma Corp and Seaport Therapeutics, Inc. Common Stock across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Arbutus Biopharma Corp logo
ABUS
Arbutus Biopharma Corp
$885M
$4.48HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT
Seaport Therapeutics, Inc. Common Stock logo
SPTX
Seaport Therapeutics, Inc. Common Stock
$930M
$17.37HealthcareDelayed quote: Oct 6, 2026, 4:00 PM EDT

Total return — ABUS vs SPTX

growth of $100 · dividends reinvested · last 1y
ABUS +11.2% (+11.2%/yr)SPTX -6.8% (-6.8%/yr)ABUS compounded faster over this window
80100120140Start $100$111$93
ABUS SPTX

ABUS vs SPTX: by the numbers

  • •SPTX is the larger company ($930M vs $885M market cap).
  • •ABUS is profitable (84.23% net margin) while SPTX runs a net loss (0.00%).

Metrics side by side

Valuation

MetricABUSSPTX
P/E ratio5.74N/A
Forward P/E6.05N/A
P/S ratio4.87N/A
P/B ratio3.422.20
EV / EBITDA5.90N/A

Profitability

MetricABUSSPTX
Gross margin99.98%0.00%
Operating margin-192.08%0.00%
Net margin84.23%0.00%
ROE59.16%N/A
ROIC54.39%-36.95%

Growth (annualized)

MetricABUSSPTX
Revenue CAGR (5Y)85.17%N/A
Total return CAGR (5Y)2.19%N/A

Frequently asked

Is ABUS or SPTX more profitable?
ABUS runs the higher net margin — ABUS at 84.23% versus SPTX at 0.00%.

Go deeper

Full ABUS analysisFull SPTX analysisInteractive comparison tool

Dig into the metrics

Arbutus Biopharma P/E ratioArbutus Biopharma ROESeaport Therapeutics, Inc. Common Stock ROEArbutus Biopharma operating marginSeaport Therapeutics, Inc. Common Stock operating marginArbutus Biopharma revenue growthSeaport Therapeutics, Inc. Common Stock revenue growthArbutus Biopharma free cash flowSeaport Therapeutics, Inc. Common Stock free cash flow

Arbutus Biopharma & Seaport Therapeutics, Inc. Common Stock appear in these rankings

Fastest Revenue Growth StocksHighest ROE StocksHighest ROIC StocksLowest P/E Ratio Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.